Rapid Update, Jun 2023: Calcium administration changed to 1 gram calcium
Purpose
This Clinical Practice Guideline (CPG) provides a brief summary of the scientific literature for prehospital blood use, with an emphasis on the en route care environment. Updates include the importance of calcium administration to counteract the deleterious effects of hypocalcemia, minimal to no use of crystalloid, and stresses the importance of involved and educated en route care medical directors alongside at a competent prehospital and en route care providers (See Table 1.) With the paradigm shift to use FDA-approved cold stored low titer group O whole blood (CS-LTOWB) along with the operational need for continued use of walking blood banks (WBB) and point of injury (POI) transfusion, there must be focused, deliberate training incorporating the different whole blood options. Appropriate supervision of autologous blood transfusion training is important for execution of this task in support of deployed combat operations as well as other operations in which traumatic injuries will occur. Command emphasis on the importance of this effort as well as appropriate logistical support are essential elements of a prehospital blood program as part of a prehospital/en route combat casualty care system.
Early administration of blood products to the trauma patient in extremis is the standard in combat casualty care and becoming more common as part of a strategy of civilian prehospital critical care.1-7 Although there is some dissent regarding the level of evidence for and benefits of prehospital blood transfusion in the civilian literature, much of the data informing that discussion precedes the use of whole blood and involves a patient population dissimilar from the military.8,9 Civilian Emergency Medical Services systems internationally10,11 and in Texas, North Carolina and several other states have initiated whole blood transfusions in the prehospital environment. At least one civilian tactical law enforcement team has initiated a Low-Titer O Fresh Whole Blood program.12 The main military literature covering this topic is summarized in Table 2 below.
NOTE: Conventional goal is systolic blood pressure >90mmhg. Recent concept indicates a higher goal of 90-110mmHg due to shift towards blood-based resuscitation and concern for prolonged hypoperfusion especially for patients with long transport times.
Prehospital blood transfusion is predicated upon clearly defined criteria for the use of this valuable resource. Several high performing military and civilian prehospital medical teams use prehospital blood transfusion according to protocolized guidelines. The U.S. Army Ranger Regiment was an early adopter of prehospital blood transfusion and uses the following criteria for transfusion: signs and symptoms of hemorrhagic shock; OR 1+ amputation; blunt/penetrating trauma (junctional/abdominal/thoracic); OR pelvic fracture; OR SBP <100; OR lactate >5; pulse >100.20 In Australia, the Greater Sydney Area Helicopter Emergency Medical Services (GSA-HEMS) is an intensivist-based prehospital critical care service that has extensive experience in prehospital blood transfusion. In the prehospital environment, they transfuse blood if there is “persistent hemorrhagic shock despite hemorrhage control measures after crystalloid infusion.”21 During interhospital transport GSA-HEMS transfuses blood if there is “persistent hemorrhagic shock where there is limited or no access to cross-matched blood and [an] ongoing requirement for transfusion.” The Australian Queensland Ambulance Service Trauma Response Team administers blood products in the prehospital environment and a retrospective review of cases was published in 2014 demonstrating benefit in appropriate clinical situations.22 In 2014, proposed criteria for prehospital blood products in combat casualties were refined based on data from Afghanistan23 and updated in 2020 using a larger data set from the entire DoD Trauma Registry (DoDTR).24 A case series reviewing the benefits of early whole blood administration in combat casualties was published in 2016.25
Development of transfusion criteria is an important consideration in establishment of a prehospital transfusion program. In the civilian trauma center experience, 596 trauma patients were evaluated using an assessment of blood consumption (ABC) score.26 Patients received one point for any of the following: penetrating mechanism; positive focused assessment sonography for trauma (FAST); systolic blood pressure less than 90 mmHg; heart rate greater than or equal to 120 beats per minute. An ABC score of two or greater predicted the need for massive blood transfusion with 75% sensitivity and 86% specificity. This investigation demonstrated the utility of a quick, non-laboratory based tool to predict the need for blood transfusion.
Careful attention to transfusion triggers can limit wastage of this important resource in a potentially resource constrained environment. Furthermore, it is important to note that blood product usage can be optimized when hemorrhage control is undertaken simultaneously.5,7 Ensure that hemorrhage control efforts are properly employed in accordance with Tactical Combat Casualty Care Guidelines. When administering blood, be certain to alert the receiving facility that the patient is requiring blood transfusion, noting any potential need for massive transfusion.
Certain special considerations for blood transfusion have been enacted in other Department of Defense transfusion algorithms.27 Rapid transfusion of blood can cause sheering of RBCs and should be avoided if possible. When possible, low titer group O whole blood (LTOWB) should be administered as the blood product of choice. LTOWB has been screened for Anti-A and Anti-B antibodies. The titer of these antibodies is low enough to represent minimal risk of clinical consequences, and may be considered a universal donor. LTOWB will be exclusively drawn from sites approved by the Armed Services Blood Program (ASBP), distributed in theater via the ASBP blood distribution system and fully tested in accordance with FDA guidelines.
Blood products should be transfused in a plasma:platelet:RBC ratio of 1:1:1. If platelets are not available, then plasma:RBC should be transfused in a 1:1 ratio. If that is not possible, then reconstituted dried plasma, liquid plasma or thawed plasma alone or RBCs alone should be transfused.
If available, type O negative RBCs should be used preferentially for females of childbearing years. If it is necessary to administer O positive blood to a woman of childbearing years with O negative blood, then consider Rhogam therapy to decrease the risk to subsequent pregnancies. Please note though that resuscitation and prevention of exsanguination takes precedence of potential future pregnancy complications. Pediatric blood transfusion should be based on clinical signs of shock rather than predefined vital signs, since vital signs can vary considerably between age groups in pediatric patients.
Blood plasma contains important clotting factors and can be transfused rapidly. Thawed plasma has a shelf life of 5 days and may not be available for prehospital missions. “Never frozen” liquid plasma has a shelf life of 26 days and may be more readily available. Check with the issuing facility for availability of thawed or liquid (i.e. never frozen) plasma. All blood products must be transfused immediately after removal from the storage container. If transfusion is delayed, then blood products that have been removed from storage and exceeded proper temperature will be returned to the issuing facility per local policy. Ensure that all blood products issues have a Safe-T-VUE (NSN 6515-08-T00-3056) attached and activated for temperature monitoring. (See Appendix E).
Proper storage, transport and administration of blood and blood products is addressed the following Joint Trauma System CPGs: Damage Control Resuscitation,28 Frozen and Deglycerolized Red Blood Cells29 and Whole Blood Transfusions.30
Ensure that the blood product container (NSN 6530-01-505-530I; OCP/5306; Desert) is properly charged and maintained prior to loading blood products. Ensure that all blood products have a Safe-T-VUE attached and activated for temperature monitoring. Ensure that thawed plasma is at a refrigerated temperature (1-6 degrees C) prior to placement of Safe-T-VUE. Appropriately document issuance and use of blood products per local protocol, including documentation in Theater Medical Data Store (TMDS) inventory.
Blood products carried outside of a medical treatment facility (MTF) and/or laboratory will be contained in an approved storage container for a maximum of 48 hours. Once loaded and sealed, a container will remain closed and intact until used for patient care or returned to the issuing facility. Units will inspect blood product containers and document appropriate quality metrics (e.g., intact, no leaking) every 24 hours.
The rate of non-infectious transfusion reaction is low.31 In a recent evaluation of 4,857 transfusion episodes approximately 1% were associated with a serious reaction.32 Transfusion-associated circulatory overload was most common (~1%); while transfusion-related acute lung injury, anaphylactic reaction and hypotensive reactions all occurred in less than 0.1% of transfusions. Other investigators evaluated emergency transfusion of 5,203 units of type-O RBC to 480 trauma patients and found that no acute hemolytic transfusion reactions occurred.33
In the unlikely event of a prehospital transfusion reaction, immediately stop the transfusion. In cases of anaphylaxis, administer 0.3 mL of 1:1000 epinephrine intramuscularly (IM), administer diphenhydramine 25 mg IV or IM and consider methylprednisolone (the FDA approved dose of methylprednisolone is 10 – 40 mg IV over several minutes, with subsequent doses being determined by clinical response). Maintain the patient’s airway as needed and administer IV fluids in cases of hypotension. In cases of acute hemolytic reaction, administer diphenhydramine 25 mg IV or IM, and consider osmotic diuresis with mannitol 20% 20 gm or 3% sodium chloride 250 mL.
Calcium administration should be considered in all patients undergoing en route care blood transfusion. The citrate preservative in blood products can chelate calcium and contribute to hypotension in patients who have received blood products.34 In 352 patients who were critically bleeding and required massive transfusion, investigators found that hypocalcemia worsened mortality. Patients generally had low ionized calcium concentration (mean = 0.88mmol/L) and had higher odds of mortality (Odds Ratio = 1.25, 95% Confidence Interval 1.04-1.52; P = 0.02). Admission hypocalcemia is further associated with mortality.35 Calcium concentration was measured in 591 trauma patients before administration of blood products. Those with an ionized calcium < 1 experienced higher mortality (15.5%) compared to those with ionized calcium levels >1 (mortality = 8.7%, p = 0.036).
Trauma patients are often hypocalcemic without regard to transfusion status, further suggesting that calcium administration may be beneficial.36,37 In 212 trauma patients with a mean Injury Severity Score (ISS) of 34; 64% were found to be hypocalcemic (with calcium < 1.15 mmol/L) and 10% were severely hypocalcemic (<0.9mml/L). Hypocalcemia is common in massive transfusion and associated with increased mortality.38,39 Although the mechanism of this effect is not completely understood, it is thought that acidemia related to tissue hypoperfusion may play a role.40 Administration of one gram of calcium IV/IO before, during (using a secondary access point) or immediately after the first unit of blood product. Re-dose one gram of calcium IV/IO after every 4 units of blood products.
Execution of prehospital and en route care blood transfusions requires sufficient training to adequately prepare. Conducting the most realistic training possible has been shown to improve in-hospital trauma team performance as well as the widely held belief of military training in general. Whole blood training should be viewed similarly.41 Coordinated and deliberate autologous blood labs with appropriate oversight can safely achieve the highest degree of realism with relatively low cost.42,43 Armed services blood bank policies for donor allowance in autologous blood lab participants is still under discussion.
Population of Interest
Intent (Outcome)
Performance/Adherence Metrics
DATA SOURCES
SYSTEM REPORTING & FREQUENCY
The above constitutes the minimum criteria for PI monitoring of this CPG. System reporting frequency will be performed annually; additional PI monitoring and system reporting may be performed as needed.
The system review and data analysis will be performed by the JTS Chief and the JTS PI Improvement Branch.
Responsibilities
It is the Unit Medical Director’s responsibility to ensure familiarity, training, appropriate compliance and PI monitoring at the local level with this CPG. Coordination with the Regional Medical Director and Trauma Director is also essential in ensuring full spectrum compliance and PI monitoring along with clear communication with the Combatant Command Trauma System and Joint Trauma System.
BEFORE
Criteria for Blood Transfusion:
DURING
AFTER
Resupply from pre-designated source: Consider 1 gm Calcium IV
Abbreviations: Heart rate (HR), Beats per minute (bpm), Systolic blood pressure (SBP), Intravenous (IV), Intraosseous (IO), Intramuscular (IM), As needed (prn), Gram (gm), Sodium chloride (NaCl)
Source: Vampire Program: CENTCOM Clinical Operations Protocol-01: Urgent Resuscitation using Blood Products during Tactical Evacuation from Point of Injury
PURPOSE
To provide essential instructions on urgent/life-saving resuscitation procedures using blood products during tactical evacuation (refers to both casualty evacuation and medical evacuation) from the point of injury (POI) for casualties suffering major blood loss/massive hemorrhage. Referred to as the Vampire Program. This guideline supports the Joint Trauma System (JTS) Damage Control Resuscitation Clinical Practice Guideline (CPG), Whole Blood Transfusion CPG, and the Tactical Combat Casualty Care (TCCC) Guidelines.
Guidance applies to medical and non-medical personnel (e.g., flight medic, crew chief, registered nurse, enlisted medical personnel, physician, nurse practitioner, or, physician assistant), assigned/attached or allocated to perform tactical medical response (TCCC) and evacuation (CASEVAC and MEDEVAC) duties that involve direct or indirect patient care.
FIELD INDICATIONS FOR TRANSFUSION DURING TACTICAL EVACUATION
The following are indications for transfusion in the presence of severe traumatic injury:
WARNING: The amputation patterns above are the only traumatic injuries that constitute a stand-alone immediate field indicator for transfusion that requires no confirmation with vital sign parameters.
CAUTION: Control external bleeding before or simultaneously with initiation of blood product transfusion.
Traumatic Arrest: patient with exsanguination who had signs of life when received from ground forces and has since become pulseless should receive immediate transfusion (transfusion is more important than chest compressions in cases of exsanguination and should take priority).
Traumatic injuries where early blood transfusions are most likely to be needed:
Initiate transfusion with 1 unit of blood product. Give additional units if clinically indicated. Avoid resuscitation with crystalloid which may increase bleeding, particularly from non-compressible torso hemorrhage.
Refer to Appendix C for list of clinical indicators for hemorrhagic shock.
PROCEDURE
Blood Component Therapy Approved for Transfusion during Tactical Evacuation
Red blood cells (RBCs) increase the recipient’s oxygen-carrying capacity by increasing the mass of circulating red cells. Plasma and platelets work together to improve blood clot formation and clot stability. On average a unit of whole blood (WB) contains a volume of 500-600 mL and a unit of RBC’s contains a volume of 300-400 mL. In an exsanguinating patient, a unit of blood can be given quickly. Ensure good blood flow through IV or IO access before initiating transfusion. Refer to Appendix D for Transfusion Procedures and Appendix F for Pearls for Transfusion.
CAUTION: Rapid infusion against resistance can cause mechanical shearing of RBCs and should be avoided.
1. Blood products will be administered in the following priority depending on availability and according to TCCC Guidelines:
NOTE: LTOWB has been screened for anti-A and anti-B antibodies; these units contained a low titer of anti-A and anti-B and are therefore considered a universal donor product that may be given to recipients of any blood type with a minimum risk for a minor ABO incompatibility (typically minor and most often subclinical clinical consequences). The whole blood supplied to MEDEVAC units will be exclusively drawn in the United States from the ASBP-approved sites and distributed in theater by the ASBP blood distribution system. The LTOWB units will be fully tested following FDA current guidelines.
2. POS (either low titer Group O WB or Type O RBCs) is the standard for transfusion during evacuation.
NOTE: Patients requiring blood can safely receive un-cross matched low titer Group O WB or Type O RBCs until type-specific products are available.
3. If available, use O NEG on females of childbearing potential age <50 years old. Inform receiving facility regarding female given O POS blood for documentation in the medical record. If a minimal amount (just a few milliliters) is given, consider Rhogam therapy. The immunologic consequences of administration of an entire unit of O POS whole blood or RBC to an O NEG female of child-bearing potential cannot safely be reversed with Rhogam. Treatment of exsanguination takes precedence over potential future pregnancy outcomes.
CAUTION: WB collected in theater will NOT be supplied for use onboard MEDEVAC aircraft.
Plasma is recognized as an important component in preventing and treating coagulopathy in trauma. On average a unit contains a volume of 200-250 mL and is transfused rapidly.
The recommended mission loads for tactical evacuation are based on operations tempo and determined by the theater or Joint Task Force surgeon. Specific missions may require additional blood products; units will refer to the Joint Blood Program Office.
Pediatric patients:
Receiving Blood Components from an Issuing Facility (U.S. and Coalition)
U.S. issuing facility personnel from the Blood Support Detachment (BSD), MTF (Role 2/3) or lab will:
Non-U.S. Issuing Facility: When U.S. blood products are to be issued from a Coalition facility, contact the Joint Blood Program Office to coordinate issuing requirements and documentation of units received.
Receiving unit (Evacuation Unit) personnel will:
Storage, Transportation and Monitoring of Blood Products
WARNINGS: - At no time will container or its contents (blood products) be placed in a refrigerator or other cooling device outside a blood bank. - Blood products will not be used if container is leaking; or the temperature indicator (Safe-T-VUE) on the blood product is out of standard (refer to Appendix E). - Notify the issuing facility and return container and products for replacement.
Individual and Unit Training Requirements
Essential Items Required for Implementing a Vampire Program
Warming Devices for Blood Transfusion
Use of infusion warming devices is highly recommended. These will be FDA approved for the actual use in transfusion of blood products (examples of devices include: Belmont® Buddy-lite™, EnFlow® or Thermal Angel).
WARNING: Warming devices will have safety mechanisms built in that prevents the output temperature from exceeding 42°C. Unit personnel will be familiar with safety mechanisms for the device used.
Tranexamic Acid (TXA)
Patients receiving blood transfusion within three hours of injury should also receive TXA. Refer to the TCCC guidelines for administration of TXA.
Record Keeping and Documentation Requirements
References
Purpose
The purpose of this Appendix is to ensure an understanding of DoD policy and practice regarding inclusion in CPGs of “off-label” uses of U.S. Food and Drug Administration (FDA)–approved products. This applies to off-label uses with patients who are armed forces members.
Background
Unapproved (i.e. “off-label”) uses of FDA-approved products are extremely common in American medicine and are usually not subject to any special regulations. However, under Federal law, in some circumstances, unapproved uses of approved drugs are subject to FDA regulations governing “investigational new drugs.” These circumstances include such uses as part of clinical trials, and in the military context, command required, unapproved uses. Some command requested unapproved uses may also be subject to special regulations.
Additional Information Regarding Off-Label Uses in CPGs
The inclusion in CPGs of off-label uses is not a clinical trial, nor is it a command request or requirement. Further, it does not imply that the Military Health System requires that use by DoD health care practitioners or considers it to be the “standard of care.” Rather, the inclusion in CPGs of off-label uses is to inform the clinical judgment of the responsible health care practitioner by providing information regarding potential risks and benefits of treatment alternatives. The decision is for the clinical judgment of the responsible health care practitioner within the practitioner-patient relationship.
Additional Procedures
Balanced Discussion
Consistent with this purpose, CPG discussions of off-label uses specifically state that they are uses not approved by the FDA. Further, such discussions are balanced in the presentation of appropriate clinical study data, including any such data that suggest caution in the use of the product and specifically including any FDA-issued warnings.
Quality Assurance Monitoring
With respect to such off-label uses, DoD procedure is to maintain a regular system of quality assurance monitoring of outcomes and known potential adverse events. For this reason, the importance of accurate clinical records is underscored.
Information to Patients
Good clinical practice includes the provision of appropriate information to patients. Each CPG discussing an unusual off-label use will address the issue of information to patients. When practicable, consideration will be given to including in an appendix an appropriate information sheet for distribution to patients, whether before or after use of the product. Information to patients should address in plain language: a) that the use is not approved by the FDA; b) the reasons why a DoD health care practitioner would decide to use the product for this purpose; and c) the potential risks associated with such use.